Apollomics (APLM) Total Liabilities (2020 - 2025)

Apollomics (APLM) posted quarterly Total Liabilities of $6.7 million for Q4 2025, up 2492.28% quarter-over-quarter from $259000.0 in Q4 2023.

Apollomics (APLM) Total Liabilities (2020 - 2025) Analysis & Trends

Apollomics (APLM) has reported Total Liabilities for 5 consecutive years, with $6.7 million the latest figure, recorded in Q4 2025.

In Q4 2025, Total Liabilities changed N/A year-over-year to $6.7 million; the TTM figure through Dec 2025 stood at $6.7 million (changed N/A YoY), while the FY2025 annual figure was $6.7 million, up 6967.37% from the prior year.
Total Liabilities rose to $6.7 million in Q4 2025 per APLM's latest filing, from $259000.0 in the prior quarter.
Across five years, Total Liabilities topped out at $511.9 million in Q4 2022 and bottomed at $259000.0 in Q4 2023.
Historically, Total Liabilities has averaged $201.8 million across 4 years, with a median of $185.0 million in 2022.
Annual changes were most pronounced in 2022 — Total Liabilities surged 58.86% — and 2023, when it slumped 99.95%.
Apollomics' Total Liabilities stood at $322.2 million in 2021, then soared by 58.86% to $511.9 million in 2022, then plunged by 99.95% to $259000.0 in 2023, then jumped by 2492.28% to $6.7 million in 2025.
Business Quant data shows APLM's Total Liabilities at $6.7 million in Q4 2025, $259000.0 in Q4 2023, and $71.4 million in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Liabilities (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	7.18 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	10.02 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.62 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	4.20 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	4.00 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	4.20 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	1.35 Bn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	10.03 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	3.22 Bn
10	Apollomics	34.08 Mn	30.81 Mn	-	6.71 Mn

Download Data